Health Condition 1: L639- Alopecia areata, unspecified Health Condition 2: L209- Atopic dermatitis, unspecified Health Condition 3: L439- Lichen planus, unspecified Health Condition 4: L409- Psoriasis, unspecified Health Condition 5: L80- Vitiligo
Conditions
Interventions
Intervention1: Apremilast 20MG & 30MG Tablet: Apremilast 20MG twice daily (age, 6-11 years and weight â?¥15 kg)
Apremilast 30MG twice daily (age, 12-17 years and weight â?¥35 kg)
Control Intervention1
Sponsors
CUTIS Academy of Cutaneous Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Children between age of 6-17 years 2.Confirmed dermatological diseases (psoriasis, vitiligo, alopecia areata, atopic dermatitis) 3.Both male and female children will be recruited 4.Parents willing to provide written informed consent
Exclusion criteria
Exclusion criteria: 1.History of any chronic systemic disease 2.History of any congenital anomaly 3.Patients with active infection 4.Participated in a clinical trial in last 90 days 5.Parents not willing to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect assessed in terms of decrease in the disease activity clinically and/or dermoscopically.Timepoint: After 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| ï?· Patient satisfaction with treatment will be assessed based on a Grading questionnaire ï?· Patient compliance will be assessed based on completed patient diary and compliance assessment during study visits ï?· Safety will be assessed based on the adverse reactions reported during the study period.Timepoint: After 4 months | — |
Countries
India
Contacts
Public ContactDr Rashmi Agarwal
CUTIS Academy of Cutaneous Sciences
Outcome results
None listed